IIa C 567,568 Routine periodic stress testing of asymptomatic patients after PCI without specific clinical indications should not be performed. III: No Benefit C 795 Cardiac rehabilitation Medically supervised exercise programs (cardiac rehabilitation) should be recommended to patients after PCI, particularly for patients at moderate to high risk, for whom supervised exercise training is warranted. I A 796 804 Secondary prevention (recommendations included from the 2011 AHA/ACCF Secondary Prevention and Risk Reduction Therapy Guideline)805 Lipid management with lifestyle modification and lipid-lowering pharmacotherapy Lifestyle modification I B 806,807 Statin therapy I A 344,806,808 810,810a Statin therapy which lowers LDL cholesterol to 100 mg/dL and achieves at least a 30% lowering of LDL cholesterol I C 344,806,808 810,810a Statin therapy which lowers LDL cholesterol to 70 mg/dL in very high-risk* patients IIa B 345,808 810,810a,811,812 Blood pressure control (with a blood pressure goal of 140/90 mm Hg) Lifestyle modification I B 813 817 Pharmacotherapy I A 813,818,819 Diabetes management (eg, lifestyle modification and pharmacotherapy) coordinated with the patient s primary care physician and/or endocrinologist I C N/A Complete smoking cessation I A 820 823 *Presence of established cardiovascular disease plus 1) multiple major risk factors (especially diabetes), 2) severe and poorly controlled risk factors (especially continued cigarette smoking), 3) multiple risk factors of the metabolic syndrome (especially high triglycerides 200 mg/dL plus non HDL cholesterol 130 mg/dL with low HDL cholesterol [ 40 mg/dL]), and 4) acute coronary syndromes. ACS indicates acute coronary syndromes; BMS, bare-metal stent(s); COR, class of recommendation; DAPT, dual antiplatelet therapy; DES, drug-eluting stent(s); GI, gastrointestinal; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LOE, level of evidence; N/A, not applicable; NSAID, nonsteroidal anti-inflammatory drug; PCI, percutaneous coronary intervention; and PPI, proton pump inhibitor. Class IIa 1. 